Any current/future new fundraising through debt or equity?

There is no mention of any current or future fundraising through debt or equity in the provided transcript. The company discussed ongoing CAPEX plans, including expansions at Mahad and Baroda facilities and a hydrogenation facility commissioning, but no details on financing these through fundraising were provided. Net debt-equity ratio stands at 0.33 as of 30th September 2023, indicating manageable leverage. No direct references to plans for new debt or equity issuance were discussed during the Q&A or management comments.

Any current/future capex/capital investment/strategic investment?

The company has ongoing CAPEX plans which have been slightly downsized to ensure sustained profitability. The hydrogenation facility at Baroda has been optimized and is scheduled to be commissioned in Q4 FY24. The Mahad investment project is on track in terms of both timeline and budget. Expansion projects at Mahad and Baroda are expected to impact the revenue mix in the future, with a larger contribution anticipated from Specialty and Bulk Aroma Chemicals. Regarding new plants going live, it is still too early to confirm whether these are fully operational or at trial batch stages, with trial

Future growth expectations in sales/revenue/volumes?

The Fragrance and Flavor division is showing robust growth with new product launches, new customer wins, and expansion in all markets. Volume requirements for the First Half of 2024 are much better compared to H2-2023, indicating improved demand. Current revenue remains somewhat stagnant, but expansions at Mahad and Baroda facilities are expected to change the revenue mix and contribute to growth. Focus on profitable products and expansion in bulk and specialty aroma chemicals is expected to increase both volume and value. Camphor division volumes remain stable despite pricing pressure, with f

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects improvement in volume requirements for H2 FY24 compared to H2 FY23, indicating potential top-line growth. Robust growth is seen in the Fragrance and Flavor division with new product launches and new customer acquisitions. Specialty Aroma Ingredients and Camphor businesses remain under severe margin pressure; pricing and profitability challenges are expected to continue for a few more quarters. Margins have bottomed out but pricing pressure may persist; efforts are underway to optimize products and improve profitability. CAPEX projects at Mahad and Baroda are on trac

Current/ Expected Orderbook/ Pending Orders?

The transcript does not provide explicit details on the current or expected order book or pending orders in precise numbers. However, Dharmil Bodani mentions participation in global RFQs (Request for Quotations) with larger product volumes, indicating strong order pipeline activity. Volumes indicated in RFQs for the first half of 2024 are much better compared to H2-2023, signifying improving order momentum. The Fine Fragrance division is described as doing reasonably well with steady growth and new product wins. Camphor and Specialty Chemical divisions face pressure but continue operating at f

Oriental Aromat.Q2 FY24Chemicals & Petrochemicals

Oriental Aromat. Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹532P/E: 337.6Market Cap: ₹1.8K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

The Fragrance and Flavor division is showing robust growth with new product launches, new customer wins, and expansion in all markets.
Volume requirements for the First Half of 2024 are much better compared to H2-2023, indicating improved demand.
Current revenue remains somewhat stagnant, but expansions at Mahad and Baroda facilities are expected to change the revenue mix and contribute to growth.
Focus on profitable products and expansion in bulk and specialty aroma chemicals is expected to increase both volume and value.
Camphor division volumes remain stable despite pricing pressure, with full capacity utilization at the Bareilly plant.
Overall, steady state demand is anticipated with expanding contribution from specialty and bulk aroma chemicals, supporting future top-line growth.

Margin guidance

Category 3

The company expects improvement in volume requirements for H2 FY24 compared to H2 FY23, indicating potential top-line growth.
Robust growth is seen in the Fragrance and Flavor division with new product launches and new customer acquisitions.
Specialty Aroma Ingredients and Camphor businesses remain under severe margin pressure; pricing and profitability challenges are expected to continue for a few more quarters.
Margins have bottomed out but pricing pressure may persist; efforts are underway to optimize products and improve profitability.
CAPEX projects at Mahad and Baroda are on track, with some facilities commissioning in Q4 FY24, which could improve operational capacity and mix, thus aiding future growth.
EBITDA margin improved slightly to 4.85% in Q2 FY24; net profit margins are low (~1%).
Overall, growth will be driven by focus on profitable products, market expansion, and product mix changes, especially increased contributions from Specialty and Bulk Aroma Chemicals.

See what Oriental Aromat. management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any current or future fundraising through debt or equity in the provided transcript.
The company discussed ongoing CAPEX plans, including expansions at Mahad and Baroda facilities and a hydrogenation facility commissioning, but no details on financing these through fundraising were provided.
Net debt-equity ratio stands at 0.33 as of 30th September 2023, indicating manageable leverage.
No direct references to plans for new debt or equity issuance were discussed during the Q&A or management comments.

Order book

The transcript does not provide explicit details on the current or expected order book or pending orders in precise numbers.
However, Dharmil Bodani mentions participation in global RFQs (Request for Quotations) with larger product volumes, indicating strong order pipeline activity.
Volumes indicated in RFQs for the first half of 2024 are much better compared to H2-2023, signifying improving order momentum.
The Fine Fragrance division is described as doing reasonably well with steady growth and new product wins.
Camphor and Specialty Chemical divisions face pressure but continue operating at full capacity (Bareilly plant), suggesting ongoing demand.
CAPEX expansions at Mahad and Baroda are on track to possibly boost future order volumes once operational, although full commercial orders from these are still premature.
Company remains optimistic about increasing bulk specialty vertical contribution to order book in the future.

See what Oriental Aromat. management said on order book — free account, 30 seconds.

Capex plans

Yes

The company has ongoing CAPEX plans which have been slightly downsized to ensure sustained profitability.
The hydrogenation facility at Baroda has been optimized and is scheduled to be commissioned in Q4 FY24.
The Mahad investment project is on track in terms of both timeline and budget.
Expansion projects at Mahad and Baroda are expected to impact the revenue mix in the future, with a larger contribution anticipated from Specialty and Bulk Aroma Chemicals.
Regarding new plants going live, it is still too early to confirm whether these are fully operational or at trial batch stages, with trial batches and approvals typically taking around six months.

Track Oriental Aromat. — get its next earnings analysis in your feed

How does Oriental Aromat. rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisOriental Aromat.

Rev 4Mar 3

See where Oriental Aromat. sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Oriental Aromat. rank in Chemicals & Petrochemicals?

Compare Oriental Aromat. against every Chemicals & Petrochemicals company (Q2 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Oriental Aromat.'s management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →